The Experts below are selected from a list of 153 Experts worldwide ranked by ideXlab platform

Joseph Kost - One of the best experts on this subject based on the ideXlab platform.

  • characterization of a polymeric plga Injectable Implant delivery system for the controlled release of proteins
    Journal of Biomedical Materials Research, 2000
    Co-Authors: Rom Eliaz, Joseph Kost
    Abstract:

    Physico-chemical properties of Injectable polymeric Implant systems, based on the principle that a water-insoluble polymer dissolved in a biocompatible solvent will precipitate upon contact with water, were studied and utilized to predict the release of proteins from these systems. Polylactide-co-glycolide copolymer (PLGA) and glycofurol were chosen since they both have pharmaceutical precedence. Changes in polymer composition, its weight percent in solution, molecular weight, and protein loading level were assessed to provide formulations with the desired release rates and duration of release. © 2000 John Wiley & Sons, Inc. J Biomed Mater Res, 50, 388–396, 2000.

  • characterization of a polymeric plga Injectable Implant delivery system for the controlled release of proteins
    Journal of Biomedical Materials Research, 2000
    Co-Authors: Rom Eliaz, Joseph Kost
    Abstract:

    Physico-chemical properties of Injectable polymeric Implant systems, based on the principle that a water-insoluble polymer dissolved in a biocompatible solvent will precipitate upon contact with water, were studied and utilized to predict the release of proteins from these systems. Polylactide-co-glycolide copolymer (PLGA) and glycofurol were chosen since they both have pharmaceutical precedence. Changes in polymer composition, its weight percent in solution, molecular weight, and protein loading level were assessed to provide formulations with the desired release rates and duration of release.

Fei Ren - One of the best experts on this subject based on the ideXlab platform.

  • a multifunctional mof based nanohybrid as Injectable Implant platform for drug synergistic oral cancer therapy
    Chemical Engineering Journal, 2020
    Co-Authors: Guozhu Tan, Yingtao Zhong, Linlin Yang, Yaodong Jiang, Jianqiang Liu, Fei Ren
    Abstract:

    Abstract Toward eradicating tumor, it is crucial to facilitate the sustained delivery of encapsulated drugs and render enhancements of therapeutic effectiveness. Local cancer therapy with combined drugs has emerged as a promising therapeutic strategy. Herein, we put forward to construct a hybrid nanocomposite in which metal-organic frameworks (MOFs) were integrated with thermosensitive hydrogels to devise an Injectable Implant. Doxorubicin (Dox) and celecoxib (Cel) were coloaded into the system for localized oral cancer therapy (Dox/Cel/MOFs@Gel). In view of the antiangiogenetic activity of Cel, Cel was in alliance with Dox in order to improve treatment efficacy. The particle size, morphological characterization from SEM and TEM, stability, drug loading efficiency, drug release behaviors in vitro of Dox/Cel/MOFs@Gel were examined. The efficacy of Dox/Cel/MOFs@Gel in oral cancer cell lines as well as cell internalization was evaluated. This medical platform exhibited a high capacity for drug loading, steady and pH-responsive release of dual drugs, and enhanced toxic effects against oral cancer cells (KB and SCC-9) in vitro. The nanocomposites displayed outstanding tumor inhibition efficacy in vivo, inducing tumor apoptosis and regulating tumor angiogenesis due to the synergistic effects of Dox and Cel. It was found that this local treatment resulted in considerably lower systemic toxicity and no apparent injury to the other organs. The biocompatibility test of the MOFs indicated reasonable biosafety as no evidence of persistent toxicity in vivo was observed. The Injectable nanocomposite (Dox/Cel/MOFs@Gel) possesses unique biological abilities in terms of pH-responsiveness, antitumor efficacy, biocompatibility, and simultaneously release hydrophobic and hydrophilic drug at the oral tumor site, suggesting that this nanocomposite is a promising vehicle for local oral cancer treatment.

  • metal organic frameworks thermosensitive hydrogel as Injectable Implant for dual drug synergistic oral cancer therapy
    Social Science Research Network, 2019
    Co-Authors: Guozhu Tan, Yingtao Zhong, Linlin Yang, Fei Ren
    Abstract:

    Local cancer therapy with multiple drugs has emerged as a novel therapeutic approach for facilitating the sustained delivery of therapeutic molecules that effectively suppress tumor growth. In this study, we developed a hybrid nanocomposite in which metal-organic frameworks (MOFs) were integrated with thermosensitive hydrogels to devise an Injectable Implant. Doxorubicin (Dox) and celecoxib (Cel) were coloaded into the system for localized oral cancer therapy (Dox/Cel/MOFs@Gel). This medical platform exhibited a high capacity for drug loading, steady and pH-responsive release of dual drugs, and enhanced toxic effects against oral cancer cells (KB and SCC-9) in vitro. The nanocomposites displayed outstanding tumor inhibition efficacy in vivo, inducing tumor apoptosis and regulating tumor angiogenesis due to the synergistic effects of Dox and Cel. It was found that this local treatment resulted in considerably lower systemic toxicity and no apparent injury to the other organs. The biocompatibility test of the MOFs that constructed the nanocomposite indicated reasonable biosafety in vivo as no evidence of persistent toxicity was observed. The results of this study demonstrate that the Injectable nanocomposite (Dox/Cel/MOFs@Gel) possesses unique biological abilities in terms of pH-responsiveness, antitumor efficacy, and biocompatibility, suggesting that the nanocomposite is a promising vehicle for local oral cancer treatment.

Rom Eliaz - One of the best experts on this subject based on the ideXlab platform.

  • characterization of a polymeric plga Injectable Implant delivery system for the controlled release of proteins
    Journal of Biomedical Materials Research, 2000
    Co-Authors: Rom Eliaz, Joseph Kost
    Abstract:

    Physico-chemical properties of Injectable polymeric Implant systems, based on the principle that a water-insoluble polymer dissolved in a biocompatible solvent will precipitate upon contact with water, were studied and utilized to predict the release of proteins from these systems. Polylactide-co-glycolide copolymer (PLGA) and glycofurol were chosen since they both have pharmaceutical precedence. Changes in polymer composition, its weight percent in solution, molecular weight, and protein loading level were assessed to provide formulations with the desired release rates and duration of release. © 2000 John Wiley & Sons, Inc. J Biomed Mater Res, 50, 388–396, 2000.

  • characterization of a polymeric plga Injectable Implant delivery system for the controlled release of proteins
    Journal of Biomedical Materials Research, 2000
    Co-Authors: Rom Eliaz, Joseph Kost
    Abstract:

    Physico-chemical properties of Injectable polymeric Implant systems, based on the principle that a water-insoluble polymer dissolved in a biocompatible solvent will precipitate upon contact with water, were studied and utilized to predict the release of proteins from these systems. Polylactide-co-glycolide copolymer (PLGA) and glycofurol were chosen since they both have pharmaceutical precedence. Changes in polymer composition, its weight percent in solution, molecular weight, and protein loading level were assessed to provide formulations with the desired release rates and duration of release.

Guozhu Tan - One of the best experts on this subject based on the ideXlab platform.

  • a multifunctional mof based nanohybrid as Injectable Implant platform for drug synergistic oral cancer therapy
    Chemical Engineering Journal, 2020
    Co-Authors: Guozhu Tan, Yingtao Zhong, Linlin Yang, Yaodong Jiang, Jianqiang Liu, Fei Ren
    Abstract:

    Abstract Toward eradicating tumor, it is crucial to facilitate the sustained delivery of encapsulated drugs and render enhancements of therapeutic effectiveness. Local cancer therapy with combined drugs has emerged as a promising therapeutic strategy. Herein, we put forward to construct a hybrid nanocomposite in which metal-organic frameworks (MOFs) were integrated with thermosensitive hydrogels to devise an Injectable Implant. Doxorubicin (Dox) and celecoxib (Cel) were coloaded into the system for localized oral cancer therapy (Dox/Cel/MOFs@Gel). In view of the antiangiogenetic activity of Cel, Cel was in alliance with Dox in order to improve treatment efficacy. The particle size, morphological characterization from SEM and TEM, stability, drug loading efficiency, drug release behaviors in vitro of Dox/Cel/MOFs@Gel were examined. The efficacy of Dox/Cel/MOFs@Gel in oral cancer cell lines as well as cell internalization was evaluated. This medical platform exhibited a high capacity for drug loading, steady and pH-responsive release of dual drugs, and enhanced toxic effects against oral cancer cells (KB and SCC-9) in vitro. The nanocomposites displayed outstanding tumor inhibition efficacy in vivo, inducing tumor apoptosis and regulating tumor angiogenesis due to the synergistic effects of Dox and Cel. It was found that this local treatment resulted in considerably lower systemic toxicity and no apparent injury to the other organs. The biocompatibility test of the MOFs indicated reasonable biosafety as no evidence of persistent toxicity in vivo was observed. The Injectable nanocomposite (Dox/Cel/MOFs@Gel) possesses unique biological abilities in terms of pH-responsiveness, antitumor efficacy, biocompatibility, and simultaneously release hydrophobic and hydrophilic drug at the oral tumor site, suggesting that this nanocomposite is a promising vehicle for local oral cancer treatment.

  • metal organic frameworks thermosensitive hydrogel as Injectable Implant for dual drug synergistic oral cancer therapy
    Social Science Research Network, 2019
    Co-Authors: Guozhu Tan, Yingtao Zhong, Linlin Yang, Fei Ren
    Abstract:

    Local cancer therapy with multiple drugs has emerged as a novel therapeutic approach for facilitating the sustained delivery of therapeutic molecules that effectively suppress tumor growth. In this study, we developed a hybrid nanocomposite in which metal-organic frameworks (MOFs) were integrated with thermosensitive hydrogels to devise an Injectable Implant. Doxorubicin (Dox) and celecoxib (Cel) were coloaded into the system for localized oral cancer therapy (Dox/Cel/MOFs@Gel). This medical platform exhibited a high capacity for drug loading, steady and pH-responsive release of dual drugs, and enhanced toxic effects against oral cancer cells (KB and SCC-9) in vitro. The nanocomposites displayed outstanding tumor inhibition efficacy in vivo, inducing tumor apoptosis and regulating tumor angiogenesis due to the synergistic effects of Dox and Cel. It was found that this local treatment resulted in considerably lower systemic toxicity and no apparent injury to the other organs. The biocompatibility test of the MOFs that constructed the nanocomposite indicated reasonable biosafety in vivo as no evidence of persistent toxicity was observed. The results of this study demonstrate that the Injectable nanocomposite (Dox/Cel/MOFs@Gel) possesses unique biological abilities in terms of pH-responsiveness, antitumor efficacy, and biocompatibility, suggesting that the nanocomposite is a promising vehicle for local oral cancer treatment.

Linlin Yang - One of the best experts on this subject based on the ideXlab platform.

  • a multifunctional mof based nanohybrid as Injectable Implant platform for drug synergistic oral cancer therapy
    Chemical Engineering Journal, 2020
    Co-Authors: Guozhu Tan, Yingtao Zhong, Linlin Yang, Yaodong Jiang, Jianqiang Liu, Fei Ren
    Abstract:

    Abstract Toward eradicating tumor, it is crucial to facilitate the sustained delivery of encapsulated drugs and render enhancements of therapeutic effectiveness. Local cancer therapy with combined drugs has emerged as a promising therapeutic strategy. Herein, we put forward to construct a hybrid nanocomposite in which metal-organic frameworks (MOFs) were integrated with thermosensitive hydrogels to devise an Injectable Implant. Doxorubicin (Dox) and celecoxib (Cel) were coloaded into the system for localized oral cancer therapy (Dox/Cel/MOFs@Gel). In view of the antiangiogenetic activity of Cel, Cel was in alliance with Dox in order to improve treatment efficacy. The particle size, morphological characterization from SEM and TEM, stability, drug loading efficiency, drug release behaviors in vitro of Dox/Cel/MOFs@Gel were examined. The efficacy of Dox/Cel/MOFs@Gel in oral cancer cell lines as well as cell internalization was evaluated. This medical platform exhibited a high capacity for drug loading, steady and pH-responsive release of dual drugs, and enhanced toxic effects against oral cancer cells (KB and SCC-9) in vitro. The nanocomposites displayed outstanding tumor inhibition efficacy in vivo, inducing tumor apoptosis and regulating tumor angiogenesis due to the synergistic effects of Dox and Cel. It was found that this local treatment resulted in considerably lower systemic toxicity and no apparent injury to the other organs. The biocompatibility test of the MOFs indicated reasonable biosafety as no evidence of persistent toxicity in vivo was observed. The Injectable nanocomposite (Dox/Cel/MOFs@Gel) possesses unique biological abilities in terms of pH-responsiveness, antitumor efficacy, biocompatibility, and simultaneously release hydrophobic and hydrophilic drug at the oral tumor site, suggesting that this nanocomposite is a promising vehicle for local oral cancer treatment.

  • metal organic frameworks thermosensitive hydrogel as Injectable Implant for dual drug synergistic oral cancer therapy
    Social Science Research Network, 2019
    Co-Authors: Guozhu Tan, Yingtao Zhong, Linlin Yang, Fei Ren
    Abstract:

    Local cancer therapy with multiple drugs has emerged as a novel therapeutic approach for facilitating the sustained delivery of therapeutic molecules that effectively suppress tumor growth. In this study, we developed a hybrid nanocomposite in which metal-organic frameworks (MOFs) were integrated with thermosensitive hydrogels to devise an Injectable Implant. Doxorubicin (Dox) and celecoxib (Cel) were coloaded into the system for localized oral cancer therapy (Dox/Cel/MOFs@Gel). This medical platform exhibited a high capacity for drug loading, steady and pH-responsive release of dual drugs, and enhanced toxic effects against oral cancer cells (KB and SCC-9) in vitro. The nanocomposites displayed outstanding tumor inhibition efficacy in vivo, inducing tumor apoptosis and regulating tumor angiogenesis due to the synergistic effects of Dox and Cel. It was found that this local treatment resulted in considerably lower systemic toxicity and no apparent injury to the other organs. The biocompatibility test of the MOFs that constructed the nanocomposite indicated reasonable biosafety in vivo as no evidence of persistent toxicity was observed. The results of this study demonstrate that the Injectable nanocomposite (Dox/Cel/MOFs@Gel) possesses unique biological abilities in terms of pH-responsiveness, antitumor efficacy, and biocompatibility, suggesting that the nanocomposite is a promising vehicle for local oral cancer treatment.